Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants

Journal of Infectious Diseases

Volumn 198, Issue 7, 2008, Pages 1016-1018

  Keitel, Wendy A ^a   Atmar, Robert L ^a   Nino, Diane ^a   Cate, Thomas R ^a   Couch, Robert B ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VACCINE; INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIBODY SCREENING; ANTIGENIC VARIATION; ARTICLE; BLOOD ANALYSIS; DRUG DOSE INCREASE; INFLUENZA VIRUS A H1N1; PRIORITY JOURNAL; VACCINATION;

ANTIBODIES, VIRAL; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 51849092045     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591465     Document Type: Article

References (16)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
3. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56 (RR-6):1-54.
4. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69.
5. Keitel WA, TR Cate, RB Couch, LL Huggins, Hess K. Continued efficacy of annual immunization with inactivated influenza virus vaccine over a five year period: a placebo-controlled trial in healthy adults. Vaccine 1997; 15:1114-22.
6. Mostow SR, Dowdle WR, Schoenbaum SC, Coleman MT, Kaye HS. Inactivated vaccines 1: volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad Med J 1973; 49:152-8.
7. Ruben FL, Potter CW, Stuart-Harris CH. Humoral and secretory antibody responses to immunization with low and high dosage split influenza virus vaccines. Arch Virol 1975; 47:157-66.
8. Keitel WA, Couch RB, Cate TR, et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal antibody responses in healthy adults. J Clin Microbiol 1994; 32:2468-73.
9. Keitel WA, Cate TR, Atmar RL, et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol 1996; 3: 507-10.
10. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
11. Treanor JJ, Schiff GM, Couch RB, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297:1577-82.
12. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529.
13. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 2006; 103:2845-50.
14. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75.
15. Leroux-Roels, Barkowski A, Vanwolleghem T, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 2007; 370:580-9.
16. Atmar RL, Keitel WA, Patel SM, et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006; 43:1135-42.